Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
In recent years, a once-obscure drug delivery technology has risen to prominence—lipid nanoparticles (LNPs). From mRNA vaccines and cancer immunotherapy to cutting-edge gene editing, LNPs are redefining the landscape of modern medicine.
What Are Lipid Nanoparticles—and Why Do They Matter?
Figure 1. Simplistic illustration of LNP and its individual components
LNPs are tiny yet powerful delivery vehicles, each only about 100 nanometers in size. Despite their minuscule scale, they're engineered to cross biological barriers and deliver RNA drugs directly to targeted cells. Think of them as nanoscale courier systems—sealed capsules that protect and transport fragile RNA molecules until they reach their destination inside the body. Their composition is a smart blend of specialized lipids, each with a unique job:
Figure 2. Components and Structural Features of LNPs
With advanced technology and rich expertise, Creative Biogene offers high-quality mRNA-LNP encapsulation services featuring optimal particle size, high encapsulation efficiency, and low surface charge. We help you achieve efficient RNA delivery and accelerate your research from idea to outcome.
How Do LNPs Deliver RNA?
The delivery process is a carefully orchestrated sequence:
1. Endocytosis: LNPs are recognized by cell surface receptors, initiating the formation of vesicles around them. This process can occur through receptor-mediated endocytosis (e.g., receptor-mediated phagocytosis) or non-receptor-mediated processes (e.g., phagocytosis).
2. Protonation of ionizable lipid: Endosomal vesicles have an acidic environment, causing protonation of the ionizable lipid. This transformation leads to a positively charged state, altering the surface charge of LNPs and promoting interaction with the negatively charged endosomal vesicle membrane.
3. Endosomal Escape: The positive charge of ionizable lipids interacts with the negatively charged endosomal vesicle membrane, potentially causing rupture or disruption of the vesicle membrane, allowing LNPs to escape into the cytoplasm.
4. Translation: Translation is the process where the nucleotide sequence of RNA is converted into proteins by ribosomes in the cell. The information in RNA guides the arrangement of amino acids, leading to the synthesis of specific proteins. This step represents the ultimate goal of RNA delivery, achieving the expression of specific genes.
This mechanism allows LNPs to navigate biological barriers effectively while minimizing toxicity and immune response.
Figure 3. The delivery mechanism of LNP-mRNA.
Where Are LNPs Being Used? And What's Next?
mRNA Vaccines: From COVID to Future Pandemics
LNPs gained global recognition as the delivery vehicle behind COVID-19 mRNA vaccines. Their success hinges on several factors:
Figure 4. Timeline of some key milestones for mRNA and lipid nanoparticle development.
Cancer Immunotherapy: Lighting Up Tumors
LNPs are increasingly used in mRNA-based cancer treatments:
Figure 5. Strategies for targeting mRNA–LNPs to tumors
siRNA Delivery: Silencing Disease at the Genetic Level
LNPs are ideal for delivering siRNA therapeutics thanks to their:
The FDA-approved drug Patisiran is a milestone in LNP-siRNA therapy.
Figure 6. Milestones in the development of siRNA therapeutics.
CRISPR-Cas9 Delivery: Precision Editing Made Safer
LNPs offer a non-viral, lower-risk method of delivering CRISPR tools. In preclinical studies, LNPs have successfully edited genes like Angptl3 to reduce blood lipid levels, showcasing potential for treating metabolic disorders and rare diseases.
Figure 7. Schematic illustration of LNP-mediated in vivo CRISPR-Cas9–based genome editing to induce loss-of-function mutations in Angptl3 to lower blood lipid levels.
Remaining Challenges: Unlocking the Full Potential of LNPs
Despite their success, LNPs still face hurdles:
Final Thoughts: LNPs Are Redefining RNA Medicine—But They're Just Getting Started
Lipid nanoparticles are no longer just lab experiments—they're now central players in RNA drug development and commercialization. With continued advances in lipid chemistry, targeting strategies, and formulation science, LNPs are poised to become the backbone of future therapies for infectious diseases, cancer, genetic disorders, and beyond.
If you're working in drug delivery, RNA therapeutics, or nanomedicine development, LNPs are a space you can't afford to ignore.
References:
Copyright © Creative Biogene. All rights reserved.